May 28, 2022
Video
Charles Geyer, MD, discusses the end point that was met within the OlympiA study.
May 25, 2022
Video
Charles E. Geyer, MD, discusses the efficacy of olaparib in the OlympiA study of patients with BRCA-positive, HER2-negative high-risk early breast cancer.
December 08, 2018
Video
Charles E. Geyer, Jr, MD, professor of medicine at Virginia Commonwealth University School of Medicine, associate director for clinical research and Harrigan, Haw, Luck Families Chair in Cancer Research at Massey Cancer Center, discusses the impact of pertuzumab (Perjeta) in the treatment of patients with HER2-positive breast cancer at the 2018 San Antonio Breast Cancer Symposium.